We examined net pancreatic norepinephrine (NE) spillover, pancreatic polypeptide (PP) release, and the decrement in C-peptide to identify factors involved in the blunted counterregulatory glucagon response in pregnancy. Conscious pregnant (Ph; 3 rd trimester; n = 8) and nonpregnant (NPh; n = 6) dogs were studied during insulin-induced (~12-fold basal insulin concentrations) hypoglycemia (plasma glucose 3.1 mM). Additional dogs were studied during hyperinsulinemic euglycemia (NPe, n = 4; Pe, n = 5; plasma glucose 6 mM). Arterial glucagon concentrations declined similarly in NPe and Pe. AUCs of the changes in glucagon and epinephrine were 7-and 3-fold greater in NPh than Ph (P < 0.05 between groups for both). Glucagon secretion fell below basal in NPe, Pe, and Ph but rose significantly in NPh. C-peptide declined 0.25 ± 0.06, 0.12 ± 0.11, 0.28 ± 0.05, and 0.13 ± 0.02 ng/ml in NPe, Pe, NPh, and Ph, respectively (P < 0.05, NPh vs Ph). AUCs of NE spillover were 516 ± 274, 265 ± 303, 506 ± 94, and -63 ± 79 ng, respectively (P < 0.05, NPh vs Ph). The AUC of PP release was ~3-fold greater in NPh than Ph (P < 0.05) but not different between euglycemic groups. The current evidence strongly suggests that the blunting of glucagon secretion during insulin-induced hypoglycemia in pregnancy is related to generalized impairment of a number of different signals, including parasympathetic and sympathoadrenal stimuli, and altered sensing of circulating and/or intraislet insulin.
INTRODUCTION
The standard of care for pregnant women with diabetes [whether type 1, type 2, or gestational (GDM)] involves maintenance of near-normoglycemia to reduce the risk of adverse perinatal and obstetrical outcomes. Intensive insulin therapy is often required to achieve the therapeutic goals. Unfortunately, insulin-treated pregnant women suffer from more frequent and severe episodes of hypoglycemia than their nonpregnant counterparts on comparable therapy (19, 43), for reasons that are incompletely understood. Intensive insulin therapy in general has been associated with higher rates of hypoglycemia (41) , and multiple episodes of hypoglycemia may result in a decrease in the counterregulatory response over time (15) . However, intensive insulin therapy is unlikely to be the sole cause of the frequent hypoglycemic episodes and the impaired counterregulatory response in pregnancy. In a study of women with GDM undergoing continuous glucose monitoring, hypoglycemia was observed even among women receiving no pharmacologic therapy (5). Moreover, studies in women, rats, and dogs have shown that the counterregulatory response to hypoglycemia is diminished in pregnancy, and this may be due to pregnancy itself, rather than to chronic insulin therapy (13, 38, 39).
Glucagon release is of special interest in regard to the impairment of the hypoglycemic counterregulatory response. In normal individuals, the initial response to a fall in blood glucose includes a suppression of insulin secretion and an increase in the release of glucagon and epinephrine (15) . People receiving exogenous insulin are unable to reduce their circulating insulin concentrations and therefore rely more heavily on counterregulatory hormones to respond to hypoglycemia. Glucagon's ability to bring about a rapid increase in hepatic glucose production makes it the key counterregulatory hormone under normal circumstances (15) .
Autonomic inputs -pancreatic sympathetic and parasympathetic neural stimuli and sympathoadrenal stimulation via epinephrine -are involved in the release of glucagon in response to hypoglycemia (26, 27) . In our previous study of hypoglycemia during late pregnancy in the dog, we observed that the epinephrine response was not different from that in nonpregnant controls, but the arterial norepinephrine concentrations were significantly reduced (13). Most of the circulating norepinephrine in hypoglycemic humans is reported to arise from adrenal secretion (18) , but the dissociation between the epinephrine and norepinephrine data indicated that sympathetic stimulation might be reduced in pregnancy. Thus, the question arose as to whether pancreatic sympathetic signaling is suppressed during pregnancy and this, in turn, reduces the glucagon response. Moreover, the decrement in intraislet insulin (with C-peptide serving as a marker of the change) is reported to be a key factor in determining glucagon output in hypoglycemia (33) . To determine the importance of autonomic signaling and the decrement in intraislet insulin, we examined the response to hypoglycemia in pregnant and nonpregnant dogs in which catheters were chronically placed in the superior pancreaticoduodenal vein (SPDV) in order to allow assessment of pancreatic norepinephrine (NE) spillover, an index of pancreatic sympathetic activity (21) . We simultaneously assessed pancreatic polypeptide release as an indicator of parasympathetic stimulation of the pancreas (21, 40) and evaluated changes in plasma C-peptide as an index of endogenous insulin secretion. Late pregnancy was chosen as the time for study because GDM is primarily encountered in the 2 nd and 3 rd trimesters and because recent data indicate that hypoglycemia, particularly in the postprandial and nocturnal periods, occurs relatively frequently during the 3 rd trimester in women with diabetes, especially GDM (10, 46, 47) . Altered counterregulatory responses are likely to contribute to the prevalence of hypoglycemia in late pregnancy.
RESEARCH DESIGN AND METHODS

Animals and Surgical Procedures
Experiments were performed on overnight-fasted (18 h), conscious female mongrel dogs, either nonpregnant (with basal progesterone and estradiol concentrations) or in the 8 th week of pregnancy (normal canine gestation ~9 weeks). The animals were divided into four groups:
pregnant euglycemic (Pe, n=5), nonpregnant euglycemic (NPe, n=4), pregnant hypoglycemic (Ph, n=8), and nonpregnant hypoglycemic (NPh, n=6). Diet and housing have been previously described (14) . This protocol was approved by the Vanderbilt University Institutional Animal Care and Use
Committee.
The animals underwent surgical insertion of sampling catheters in the femoral artery, left common hepatic vein, and hepatic portal vein ~17 d prior to experimentation. The SPDV was ligated adjacent to the duodenum at the caudal extreme of the duodenal lobe of the pancreas, and a silicone rubber cannula (0.04" ID and 0.085" OD; Baxter Scientific, Deerfield, IL) was introduced and positioned so that the tip rested ~3 cm from the juncture of the SPDV and the portal vein.
Ultrasonic flow probes (Transonic Systems, Ithaca, NY) were placed around the portal vein and hepatic artery as previously described (4, 14) . A flow probe was also placed on the SPDV immediately caudal to the SPDV-portal juncture and approximately 1.5 cm rostral from the tip of the cannula (21) . The external ends of the catheters and flow probes were placed in subcutaneous pockets. On the day of the experiment, the catheter ends were removed from the pockets under local anesthesia, and the catheters were emptied of their contents and flushed with saline. The animal was placed in a Pavlov harness and intravenous access was obtained through the cephalic veins. Criteria for inclusion and experimental preparation were as previously described (10) .
Experimental Design
Each experiment consisted of a 120-minute period of dye and tracer equilibration (-150 to - The rates of gluconeogenic flux (GNG flux ) from circulating precursors and net hepatic glycogenolysis were estimated using the arteriovenous difference technique described previously (14) . Glucose R a and R d were calculated using a 2-compartment model (32) with dog parameters (20) .
The area under the curve (AUC) was determined by means of the trapezoidal calculation.
Statistical comparisons were made with ANOVA with post hoc analysis by Tukey's test, using
SigmaStat (SYSTAT, Point Richmond, CA). Repeated measures ANOVA was applied to time course data. Best subset regressions were calculated with SigmaStat, using adjusted R 2 as the criterion for fit.
RESULTS
Hormone data
Arterial concentrations. Serum progesterone concentrations obtained on the day of study were 0.6±0.1 and 8.8±1.0 ng/ml in the nonpregnant and pregnant dogs, respectively (P<0.05).
Basal insulin concentrations were greater in the nonpregnant dogs than in their pregnant counterparts (Table 1 and Fig. 1 ), as previously reported (13, 14) . Insulin concentrations during the hyperinsulinemic period were significantly higher in Pe than in NPe (Table 1 ; P<0.05). However, there were no significant differences in either the circulating plasma concentrations of insulin (481±45 and 437±38 pmol/l) or the increment over basal concentrations (414±45 vs 412±36 pmol/l) in NPh and Ph, respectively ( Fig. 1 ).
Basal arterial glucagon concentrations were similar in all four groups (Table 1 and Fig. 2 ).
Arterial plasma glucagon concentrations declined significantly in both euglycemic groups during insulin infusion, and the concentrations were not different between groups at any time (Table 1) .
Arterial plasma glucagon concentrations rose briskly in NPh as glucose concentrations fell (maximum increase 28 ng/l), with the response waning after the first 90 min (Fig. 2 ). In contrast, the glucagon concentrations in Ph did not rise significantly above basal. Overall, the AUC of the change in arterial glucagon from basal was >7-fold larger in NPh than in Ph (2776±426 vs 382±489 ng; P<0.05).
Arterial cortisol concentrations were higher (P<0.05) in Pe than NPe in the basal period (Table 1) , but the concentrations rose similarly (50-65%) during hyperinsulinemic euglycemia and were not significantly different between groups at any time during the experimental period. The cortisol concentrations in the hypoglycemic groups did not differ in the basal period; both hypoglycemic groups showed an increase in cortisol during the first half of the experimental period and a waning of this response during the final 90 minutes, but the response was significantly blunted in Ph vs NPh (P < 0.05 for repeated measures ANOVA; Fig. 2 ).
Arterial epinephrine was not significantly different among the four groups during the basal period. The euglycemic groups responded to hyperinsulinemia with a modest 40-100% increase in epinephrine during the experimental period, with experimental period concentrations in Pe being higher than those in NPe (Table 1) . Both hypoglycemic groups experienced a much more significant rise in epinephrine than the euglycemic groups, but the increase was ~3-fold greater in NPh than in Pancreatic secretion and signaling. The basal C-peptide concentrations in Pe tended to be lower than in NPe (P=0.12), and those in Ph were significantly lower than in NPh (Table 2 ). Cpeptide concentrations declined significantly from basal during the experimental period in all groups except Pe, and the concentrations did not differ among the four groups during the last 2 h of insulin infusion (Table 2) .
Basal arterial levels of pancreatic polypeptide (PP), net PP release, and net pancreatic norepinephrine spillover did not differ significantly in the P and NP groups during euglycemia, and glucagon secretion declined similarly in both groups (Fig. 3) . PP concentrations in the hypoglycemic groups increased 2-to 4-fold, and the change from basal in PP secretion was significantly greater in NPh than in Ph (AUC of the response 2087±876 vs 590±483 ng in NPh vs Ph, P<0.05). Net pancreatic NE spillover rose significantly (P<0.05) during the experimental period in the NPh group. The Ph group exhibited an initial decline in NE spillover but returned to basal rates within 90 min; the rates never increased above basal ( Fig. 3 ; P<0.05 for Ph vs NPh). During hyperinsulinemia, net pancreatic glucagon secretion fell below basal in Ph but rose significantly in NPh ( Fig. 3 ; P<0.05).
Best subset analysis was carried out in NPh and Ph to determine which factors assessed were most closely linked to glucagon secretion (Table 3 ). In NPh, the factors found to contribute in the model of best fit included only the change from basal in the plasma glucose concentration, AUC of the epinephrine response, and net pancreatic NE spillover. In Ph, not only did the change in glucose and pancreatic NE spillover enter the model, but also PP release, the decrement in C-peptide, and the arterial plasma insulin concentration during hyperinsulinemia. 
Glucose metabolism
The basal plasma glucose concentrations were significantly lower in the pregnant than in the nonpregnant groups, but glucose concentrations in NP and P did not differ after 165 min (Table 1 and Fig. 1 ). The hypoglycemic groups experienced a 45-50% reduction in arterial plasma glucose (Fig. 1) . Net hepatic glucose output (NHGO) was evident in all groups during the basal period, but the rate was significantly greater in the P vs NP groups (12.4±1. 7) . By the end of study, it had doubled in NPh but increased only 50% in Ph (P<0.05).
DISCUSSION
The peak glucagon concentration during the first 90 minutes of hypoglycemia in the nonpregnant dogs was ~2-fold (P<0.05) that of the pregnant animals. In fact, the glucagon concentrations did not rise significantly above basal in the pregnant hypoglycemic group. The excursions of epinephrine, norepinephrine, and cortisol were also significantly reduced in the Ph group, but not as completely as that of glucagon. Consistent with the blunted hormonal response, glycogenolysis was reduced in the Ph group and consequently net hepatic glucose output and endogenous glucose R a declined from basal. In contrast, in the NPh group, after a transient fall, net hepatic glucose output increased above basal and endogenous R a returned to basal rates. As a result there was a difference in glucose production of 8-9 µmol . kg -1. min -1 between the pregnant and nonpregnant dogs during hypoglycemia.
Redundant mechanisms appear to control glucagon secretion in the normal state. The alpha cell is able to respond sensitively to the glycemic level in hypoglycemia, but this ability is ablated in the presence of even very mild hyperinsulinemia (29) . The decrement in intraislet insulin which occurs during hypoglycemia is reported to be related to the magnitude of the glucagon response (3, 23, 33, 36) . However, the exact extent to which a decrement in intraislet insulin accounts for the glucagon response to hypoglycemia remains unclear, as previously noted (23). Additionally, since insulin-induced hypoglycemia has been used in some of the studies of the effect of intraislet insulin on the glucagon response (e.g., 23, 36), the intraislet insulin concentration (including both endogenous and exogenous insulin) is unknown. In any event, the interpretation of the in vivo intraislet insulin experiments has relied primarily on the correlation between the glucagon response and the change in C-peptide, and therefore it is impossible to determine cause and effect from the data. Because of the low basal C-peptide concentrations in the pregnant vs nonpregnant dogs (and the resulting very small decrement in C-peptide in the pregnant dogs), we cannot rule out the possibility that the impairment in glucagon release was at least partially due to a lack of change in endogenous insulin secretion. With the exception of the earliest portion of the hyperinsulinemic clamp period, however, the C-peptide concentrations did not differ between pregnant and nonpregnant dogs during hypoglycemia (Table 2) In addition to direct effects of glucose and/or insulin on the alpha cell, autonomic input via the parasympathetic innervation of the pancreas and the sympathoadrenal system (epinephrine and norepinephrine release from the adrenals and sympathetic stimuli to the pancreas) has been shown (25, 28) . In a series of experiments in the human, dog, rat, mouse, and rhesus monkey, Havel et al (24) (25) (26) (27) (28) demonstrated that at least one pancreatic autonomic input is essential for an intact glucagon response during insulin-induced hypoglycemia. The importance of autonomic control of the counterregulatory response has also been demonstrated in the conscious dog without the use of pharmacologic blockade. When the brain was maintained euglycemic (with carotid and vertebral arterial glucose infusion) during insulininduced hypoglycemia, the glucagon response in the dogs were reduced 79%, compared with the response when the brain was allowed to participate in the hypoglycemia (7).
In the present experiments, the pregnant dogs exhibited no significant reduction in indicators of pancreatic autonomic activation in the basal state or in response to hyperinsulinemic euglycemia.
Epinephrine, norepinephrine, and cortisol concentrations rose to a similar extent in pregnant and nonpregnant dogs during the euglycemic clamp. The rise in epinephrine during hyperinsulinemic euglycemia was consistent with some (2, 30, 42), but not the majority (e.g., 16, 17, 35) of previous reports. In contrast to the euglycemic studies, the reduction in pancreatic PP release, arterial catecholamine concentrations, and net pancreatic NE spillover in Ph vs NPh indicate that all three autonomic inputs were suppressed during hyperinsulinemic hypoglycemia in pregnancy. Table 3 suggests that epinephrine and sympathetic signaling to the pancreas are the predominant autonomic stimuli for glucagon release in hypoglycemia in the nonpregnant state. However, with the blunting of these stimuli during pregnancy, other factors such as parasympathetic signaling and perhaps the decrement in insulin secretion assume increased importance. Even with reliance on these additional stimuli, however, it is clear that the glucagon response to hypoglycemia is suppressed in pregnancy.
The cortisol response to hypoglycemia, although significantly blunted during pregnancy, was less affected than the catecholamines and glucagon in the current investigation. These data are generally consistent with the observations that ACTH stimulation of cortisol release is intact in normal pregnant women (31) and dogs (37) and the increment in cortisol in response to stress (moderate exercise) is actually enhanced in pregnant women (6) . We have previously found that the cortisol responses of pregnant and nonpregnant dogs are indistinguishable during more severe hypoglycemia (2.3 mM) (13), and thus there may be a reduction in the glycemic threshold for cortisol release during pregnancy rather than an inability to mount a normal cortisol response.
During the basal period, the plasma cortisol concentrations were significantly higher in the Pe group than in the other 3 groups. The elevation of cortisol in the Pe group was most likely related to the low basal glucose concentrations in that group (4.2±0.3 compared with 5.8±0.3 mM in the Ph group). The Pe and Ph dogs were fasted an identical number of hours, were healthy as determined by our specified criteria and by daily veterinary supervision, and were randomly assigned to euglycemia or hypoglycemia. Thus, the discrepancy in basal glycemia had no apparent basis in treatment effects. However, at the end of the studies, the mean number of fetuses in the Pe and Ph groups was found to be 8.6±0.4 vs 6.1±0.8, respectively (P < 0.05), suggesting that the fetal burden played an important role in determining basal maternal glycemia. We have no data regarding cortisol concentrations in the pregnant dogs other than on the day of experimentation, but we have not found basal cortisol concentrations to be elevated during pregnancy in our previous investigations (12, 13). Both total and free cortisol are 2-to 4-fold higher in pregnant women compared with nonpregnant controls (31) . Consistent elevations of cortisol have not been found during pregnancy in dogs (11, 37) , with the exception of a peak in secretion 8-24 h before parturition (11) . The animals in this investigation were timed-pregnant and were studied at least 1 week before their due date to avoid the hormonal perturbations associated with parturition.
Cortisol's actions reduce glucose uptake in the insulin-sensitive tissues (15) and thus could have made a contribution to the insulin resistance evident in the Pe group. Glucocorticoids are also In conclusion, the counterregulatory response to insulin-induced hypoglycemia has long been known to be suppressed during pregnancy. This investigation is the first in which it has been possible in pregnant animals to examine comprehensively and simultaneously numerous stimuli involved in regulation of glucagon secretion. In the nonpregnant animals, where an array of redundant mechanisms was intact, best subset regression suggested epinephrine played a key role in stimulating glucagon secretion. In moderate hypoglycemia in pregnancy, however, the epinephrine response was markedly suppressed, and the redundant sympathetic and parasympathetic stimuli, as well as the decrement in C-peptide concentrations, were also blunted. Whether the alpha cell's (and the brain's) capacity to detect changes in glucose or insulin during hypoglycemia is impaired during pregnancy remains unclear. Nevertheless, the data point to a generalized blunting of hypoglycemic sensing in the pregnant state. Future work is needed to examine the effects of each autonomic input and the decrement in endogenous insulin secretion on glucagon secretion in the pregnant dog. release, change in arterial plasma C-peptide (calculated as described for glucose), the mean arterial plasma insulin concentrations during the insulin infusion, and AUC of net pancreatic norepinephrine (NE) spillover. AUCs are calculated as the change from basal values or rates.
--, using adjusted R 2 as the best criterion, parameter did not enter into the regression 
